Abstract
Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
CNS & Neurological Disorders - Drug Targets
Title:Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
Volume: 15 Issue: 9
Author(s): Mohammad Nasser, Fabienne Bejjani, Mohamad Raad, Hadi Abou-El-Hassan, Sarah Mantash, Amaly Nokkari, Naify Ramadan, Nouhad Kassem, Stefania Mondello, Eva Hamade, Hala Darwish, Kazem Zibara and Firas Kobeissy
Affiliation:
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
Abstract: Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Export Options
About this article
Cite this article as:
Nasser Mohammad, Bejjani Fabienne, Raad Mohamad, Abou-El-Hassan Hadi, Mantash Sarah, Nokkari Amaly, Ramadan Naify, Kassem Nouhad, Mondello Stefania, Hamade Eva, Darwish Hala, Zibara Kazem and Kobeissy Firas, Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk, CNS & Neurological Disorders - Drug Targets 2016; 15(9) . https://dx.doi.org/10.2174/1871527315666160815093525
DOI https://dx.doi.org/10.2174/1871527315666160815093525 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Growth Factor Changes in Cerebrospinal Fluid of Children with Mental Retardation before and after Neural Precursor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Perfusion-diffusion Mismatch Predicts Early Neurological Deterioration in Anterior Circulation Infarction without Thrombolysis
Current Neurovascular Research Mitochondria: “Mood Altering Organelles” that Impact Disease Throughout the Nervous System
Current Neurovascular Research PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Cytosolic Phospholipase A2 Inhibitors as Therapeutic Agents for Neural Cell Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of Melatonin in Pancreatic Protection: Could Melatonin be Used in the Treatment of Acute Pancreatitis?
Current Pharmaceutical Design The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Multiple Roles of Histamine in Autoimmune Demyelinating Disease of the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design